Alcoholism Clinical Trial
Official title:
Targeted Naltrexone for Early Problem Drinkers
Verified date | June 2011 |
Source | University of Connecticut Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
Early problem drinkers are prevalent in the United States. Recent controlled trials have
shown that brief interventions in the primary care setting can reduce drinking and
alcohol-related problems in patients who lack evidence of alcohol dependence.
Although naltrexone (Revia) has been approved for the treatment of alcohol dependence, few
pharmacotherapy studies have been undertaken with early problem drinkers. This study is an
8-week trial of naltrexone versus placebo, combined with coping skills treatment that either
focuses on targeted use of medication or serves as background to daily use of the
medication. A total of 160 early problem drinkers recruited through screening in primary
care medical settings will be randomly assigned to one of four treatment groups. Followup
evaluations will be conducted at the end of treatment and again 3, 6, and 12 months.
Status | Completed |
Enrollment | 160 |
Est. completion date | September 2002 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Limited to early problem drinkers (i.e., those with no more than mild alcohol dependence). - Have an average weekly alcohol consumption of greater than or equal to 24 standard drinks for men and 18 standard drinks for women. - Able to read English at the eighth grade or higher level and show no evidence of significant cognitive impairment. - Willing to provide a collateral informant for interviews regarding the patient's drinking during the study. - A woman of child-bearing potential must be non-lactating, practicing a reliable method of birth control, and have a negative pregnancy test prior to initiation of treatment. - Willing to provide a signed informed consent to participate in the study. Exclusion Criteria: - Have a current clinically significant physical disease or abnormality. - Have a serious psychiatric illness. - Have a current diagnosis of drug dependence (other than nicotine dependence) or a lifetime diagnosis of opioid dependence. - A current diagnosis of alcohol dependence that is moderate or greater in severity or a history of alcohol withdrawal, or recurrent use of alcohol to alleviate alcohol withdrawal symptoms. - Used opioids or other psychoactive medications regularly in the month prior to study enrollment. - History of hypersensitivity to naltrexone (Revia). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Department of Psychiatry, University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Connecticut Health Center | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Recruiting |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 |